Musculoskeletal News and Research

RSS

Study on human growth hormone for ACL tear recovery receives funding from Mark Cuban Foundation

Funding from the Mark Cuban Foundation, run by the well-known owner of the Dallas Mavericks, will allow University of Michigan scientists and physicians to study how human growth hormone may aid recovery from an ACL tear - one of the most frequent, traumatic and dreaded knee injuries among athletes.

1 Jun 2015

ACA urges NINDS to include recommendations for use of conservative forms of pain management

The American Chiropractic Association (ACA), in recent comments submitted to the National Institute of Neurological Disorders and Stroke (NINDS) Office of Pain Policy on the draft National Pain Strategy, strongly urges the agency to include recommendations encouraging patients and health care providers to first exhaust conservative forms of pain management, when appropriate.

1 Jun 2015

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors.

1 Jun 2015

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.

1 Jun 2015

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib (IMBRUVICA) in combination with bendamustine and rituximab (BR) experienced an 80% reduction in the risk of progression or death compared to patients receiving placebo in combination with BR.

1 Jun 2015

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Pharmacyclics, Inc. today announced the initiation of PCYC-1136-CA, a multi-center study that will investigate the use of ibrutinib (IMBRUVICA®) in combination with MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor being developed by AstraZeneca.

1 Jun 2015

Therapy for genetically-caused emphysema slows progression of lung disease

A landmark clinical study in the Lancet provides convincing evidence that a frequently overlooked therapy for genetically-caused emphysema is effective and slows the progression of lung disease.

29 May 2015

Earlier antiretroviral treatment benefits HIV-infected individuals

A major international randomized clinical trial has found that HIV-infected individuals have a considerably lower risk of developing AIDS or other serious illnesses if they start taking antiretroviral drugs sooner, when their CD4+ T-cell count--a key measure of immune system health--is higher, instead of waiting until the CD4+ cell count drops to lower levels. Together with data from previous studies showing that antiretroviral treatment reduced the risk of HIV transmission to uninfected sexual partners, these findings support offering treatment to everyone with HIV.

28 May 2015

Study indicates that arthritis patients may not be taking medication as regularly as prescribed

Researchers from the Arthritis Research UK Centre for Epidemiology at The University of Manchester found that 40% of patients scored low on an adherence questionnaire at least once during their time in a recent study, indicating that they might not be taking their expensive biological therapies as regularly as prescribed.

26 May 2015

Orthocell presents at Stem Cell and Regenerative Medicine Congress in London

Orthocell’s current and future approaches to the regeneration of tendon tissue were presented with particular focus on the recent breakthrough by the Company in demonstrating its new technology to grow human tendons outside of the body...

25 May 2015

Short course of oral steroids unlikely to provide much benefit for patients with acute sciatica

Among patients with acute sciatica caused by a herniated lumbar disk (a condition also known as "acute radiculopathy"), a short course of oral steroids resulted in only modest improvement in function and no significant improvement in pain, according to a study published today in the Journal of the American Medical Association.

19 May 2015

Fibromyalgia now considered as a lifelong central nervous system disorder

Fibromyalgia is the second most common rheumatic disorder behind osteoarthritis and, though still widely misunderstood, is now considered to be a lifelong central nervous system disorder, which is responsible for amplified pain that shoots through the body in those who suffer from it.

18 May 2015

New Johns Hopkins Lyme Disease Clinical Research Center launched

Fundamental research into the causes and cures of post-treatment Lyme disease syndrome now has its first home base at a major U.S. medical research center with the launch of the Johns Hopkins Lyme Disease Clinical Research Center. Inaugurated on May 12, 2015, with a major gift from the Lyme Disease Research Foundation, the center plans an ambitious research program targeting this increasingly common disease, which costs the U.S. economy up to $1.3 billion per year in treatment costs alone.

14 May 2015

Orthocell’s Ortho-ATI therapy improves clinical outcomes in patients with tennis elbow degeneration

Regenerative medicine company Orthocell Limited is pleased to announce positive 3-5 year data from a study of its tendon cell treatment for tennis elbow has been presented at the International Cartilage Repair Society annual scientific meeting.

13 May 2015

Global survey finds gap in physicians' understanding on impact of lupus on patients' lives

As many people in the lupus community prepare to come together in support of World Lupus Day (May 10), a global survey shows that systemic lupus erythematosus (SLE) patients have difficulty describing their symptoms to their physicians, which leads to a gap in physicians understanding the full impact the illness has on patients' lives.

11 May 2015

Partners congratulate researchers on forming new biotechnology company

The Children's Hospital of Eastern Ontario, The Ottawa Hospital, the University of Ottawa and McMaster University congratulate its researchers on forming Turnstone Biologics Inc., a biotechnology company focused on developing new treatments for cancer that harness the patient's own immune system.

6 May 2015

New research can help explain prevalence of carpal tunnel syndrome and sciatica

New research from the University of Eastern Finland and Kuopio University Hospital can help explain the prevalence of widespread syndromes such as carpal tunnel syndrome and sciatica. According to the results, neural movements can be measured by using non-invasive techniques, which are also applicable in diagnostics and rehabilitation planning.

6 May 2015

Ortho-ATI™ long term study showing effectiveness for tennis elbow published in prestigious American Journal of Sports Medicine

The publication provides evidence of the durability and long term positive effect of Orthocell’s Ortho-ATI™ tendon regeneration treatment for degenerate tendon injuries...

30 Apr 2015

Zimmer Holdings reports net sales of $1.13 billion for first quarter 2015

Zimmer Holdings, Inc. today reported financial results for the quarter ended March 31, 2015. The Company reported first quarter net sales of $1.13 billion, a decrease of 2.3% reported and an increase of 4.5% constant currency compared to the first quarter of 2014.

30 Apr 2015

Teen-LABS research study reveals musculoskeletal disease outcomes among obese adolescents

Outcomes regarding musculoskeletal disease among severely obese adolescents participating in the "Teen Longitudinal Assessment of Bariatric Surgery" (Teen-LABS) study were published this week in JAMA Pediatrics. Teen-LABS is a multi-center clinical study funded by the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health that is examining the safety and health effects of surgical weight loss procedures.

28 Apr 2015

Musculoskeletal News and Research

Study on human growth hormone for ACL tear recovery receives funding from Mark Cuban Foundation

ACA urges NINDS to include recommendations for use of conservative forms of pain management

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Therapy for genetically-caused emphysema slows progression of lung disease

Earlier antiretroviral treatment benefits HIV-infected individuals

Study indicates that arthritis patients may not be taking medication as regularly as prescribed

Orthocell presents at Stem Cell and Regenerative Medicine Congress in London

Short course of oral steroids unlikely to provide much benefit for patients with acute sciatica

Fibromyalgia now considered as a lifelong central nervous system disorder

New Johns Hopkins Lyme Disease Clinical Research Center launched

Orthocell’s Ortho-ATI therapy improves clinical outcomes in patients with tennis elbow degeneration

Global survey finds gap in physicians' understanding on impact of lupus on patients' lives

Partners congratulate researchers on forming new biotechnology company

New research can help explain prevalence of carpal tunnel syndrome and sciatica

Ortho-ATI™ long term study showing effectiveness for tennis elbow published in prestigious American Journal of Sports Medicine

Zimmer Holdings reports net sales of $1.13 billion for first quarter 2015

Teen-LABS research study reveals musculoskeletal disease outcomes among obese adolescents

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News